Novel Europium-Grafted 3D Covalent Organic Framework for Selective and Sensitive Fluorescence-Enhanced Detection of Levofloxacin
Abstract
Levofloxacin (LVFX), a fluoroquinolone antibacterial agent widely used in treating bacterial infections, poses significant risks when overused, necessitating the development of reliable and efficient detection methods. Herein, we introduce Eu@SUZ−103, a novel europium-grafted three-dimensional covalent organic framework (COF) featuring an eight-connected bcu net, for the selective detection of LVFX in serum and urine. Its 3D architecture facilitates rapid LVFX diffusion to luminescent sites, producing notably enhanced fluorescence and high sensitivity. Evaluations in complex biological matrices revealed excellent performance encompassing a broad linear range (5–2000 μM) and a low detection limit. Altogether, Eu@SUZ−103 extends the practical scope of 3D COFs in fluorescence-based sensing, offering a robust platform for accurate, efficient, and selective LVFX monitoring in clinical and environmental applications.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.